Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Huelva
Clinical trial register · Spain

Clinical Trials in Huelva, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fundación EPIC6 Novartis Pharmaceuticals5 AstraZeneca5 Boehringer Ingelheim4 Eli Lilly and Company4
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Huelva

73 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae
NCT07396571Hemato-oncologic Patients, Colonization, Neutropenia, Enterobacteria Non Susceptible to Carbapenem Carrier
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Observational
535
Almería, Jerez de la Frontera, Vigo, Pamplona, Barcelona, Cadiz, Granada, Huelva
2026-09-04
Recruiting
Boehringer Ingelheim
Phase 3
448
Badalona, Barakaldo, Barcelona, Huelva, L'Hospitalet Del Llobregat, Madrid, Sabadell, Valencia
2026-07-27
Recruiting
AstraZeneca
Phase 3
150
Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria
2026-06-15
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Seville, Valladolid
2026-03-05
Recruiting
LONG NAGOMI™ PMCF STUDY
NCT07399002Coronary Artery Disease, Ischemic Heart Disease
Fundación EPIC
Observational
1,039
Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander
2026-02-27
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Barcelona, Huelva, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca
2026-02-03
Recruiting
Biosensors Europe SA
Not applicable
93
Barcelona, Córdoba, Huelva, Madrid, Seville, Valencia, Valladolid
2025-12-15
Recruiting
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes
Outcomes'10
Observational
334
Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia
2025-11-20
Recruiting
Eli Lilly and Company
Phase 3
4,500
A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia
2025-10-03
Recruiting
Sanofi
Phase 3
980
Ourense, Gijón, Huelva, Madrid
2025-10-01
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville
2025-09-13
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
A Coruña, Barcelona, Centelles, Córdoba, Ferrol, Granada, Huelva, Jaén
2025-09-02
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Badajoz, Badalona, Barcelona, Castellon, Cáceres, El Palmar, Girona, Huelva
2025-08-26
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Badalona, Barcelona, Beiro, Córdoba, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria
2025-07-22
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida
2025-07-02
Active, closed
Novartis Pharmaceuticals
Observational
219
Cadiz, Granada, Huelva, Jaén, Marbella, Mallorca, Puerto Real, Santander
2025-06-16
Recruiting
Boehringer Ingelheim
Phase 3
1,755
A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat
2025-06-09
Recruiting
AstraZeneca
Phase 3
15,100
A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia
2025-06-04
Recruiting
Idoven 1903 S.L.
Observational
2,200
Palma de Mallorca, San Sebastián, Huelva
2025-05-27
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
A Coruña, Barcelona, Huelva, Majadahonda, Palma de Mallorca, Salamanca
2025-05-12
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC
2025-04-30
Recruiting
University of Seville
Observational
728
Cadiz, Córdoba, Huelva, Seville
2025-04-30
Active, closed
Amgen
Phase 3
3,853
Almería, Castilleja de la Cuesta, Huelva, Sanlúcar de Barrameda, Seville, A Coruña, Pozuelo de Alarcón, Pamplona
2025-03-12
Recruiting
AbbVie
Observational
1,200
Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia
2025-01-31
Recruiting
Hospital Universitario de Valme
Observational
9,000
Almería, Cadiz, Cartagena, Córdoba, Cuenca, Elche, Granada, Huelva
2025-01-01
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Barcelona, Huelva, Madrid, Pamplona, Santander, Seville
2024-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Donostia / San Sebastian, Barcelona, Huelva, Seville
2024-11-21
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén
2024-11-19
Recruiting
Hospital Universitario 12 de Octubre
Not applicable
440
Bilbao, Granada, Huelva, Madrid, Málaga, Seville
2024-11-01
Recruiting
Abivax S.A.
Phase 2
212
Barcelona, Córdoba, Fuenlabrada, Huelva, Las Palmas de Gran Canaria, Santiago de Compostela, Seville, Valencia
2024-10-30
Recruiting
Fundación EPIC
Not applicable
94
Barcelona, Gijón, Huelva, León, Lugo, Mérida, Oviedo, Pontevedra
2024-10-23
Active, closed
Eli Lilly and Company
Phase 2
143
Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville
2024-10-10
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares
2024-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
LHospitalet de Llobregat, Santiago de Compostela, Huelva, Seville
2024-06-11
Recruiting
Fundación EPIC
Not applicable
150
Alicante, Badajoz, Huelva, Seville
2024-05-31
Active, closed
Fundación EPIC
Observational
153
Alicante, Aravaca, Barcelona, Cadiz, Córdoba, El Palmar, Gijón, Huelva
2024-04-04
Active, closed
Gilead Sciences
Phase 2
228
Ferrol, Huelva, Santa Cruz de Tenerife, Seville, Valencia
2024-03-27
Recruiting
Hospital Universitario La Fe
Not applicable
1,272
Huelva, Valencia, A Coruña, Burgos, Castelló, Córdoba, Elche, Granada
2024-03-11
Active, closed
Fundación EPIC
Observational
501
Albacete, Alicante, Barakaldo, Boadilla del Monte, Ciudad Real, Granada, Huelva, L'Hospitalet de Llobregat
2024-02-26
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Badalona, Jerez de la Frontera, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Huelva, Jaén
2023-12-11
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Vigo, Alicante, Barcelona, Huelva, León, Madrid, Valladolid
2023-11-30
Active, closed
iVascular S.L.U.
Phase 3
2,312
A Coruña, Almería, Barcelona, Cáceres, Huelva, Jerez de la Frontera, Las Palmas de Gran Canaria, León
2023-10-13
Recruiting
Abbott Medical Devices
Observational
1,000
Badajoz, Barcelona, Huelva, Las Palmas, Majadahonda, Málaga, Valencia
2023-09-29
Recruiting
AstraZeneca
Observational
52,121
A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda
2023-08-21
Recruiting
Coroflex® ISAR NEO PMCF Study
NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease
Fundación EPIC
Observational
3,000
A Coruña, Badajoz, Badalona, Barakaldo, Barcelona, Cáceres, Ciudad Real, Huelva
2023-08-04
Active, closed
Swedish Orphan Biovitrum
Observational
165
Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria
2023-06-26
Active, closed
AbbVie
Observational
1,019
Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Majadahonda, El Palmar, Vigo, Huelva, Madrid
2023-06-09
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Barcelona, Huelva, León, Salamanca, Seville
2023-04-25
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Ferrol, Santiago, Santiago Compostela, Elche, Granada, Huelva, Marbella, Málaga
2023-03-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Santiago de Compostela, Madrid, Barcelona, Huelva
2023-02-14
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Fuenlabrada, Barcelona, Girona, Huelva, Madrid
2023-01-16
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
Huelva, Santiago de Compostela, Valencia
2023-01-11
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia
2022-12-23
By invitation
Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center
NCT05404503Incidence of Cholangiocarcinoma on Choledochal Cysts, Postoperative Complications in Choledochal Cysts, Choledochal Cyst Monitoring
María Teresa Moreno Asencio
Observational
300
Huelva
2022-10-01
Active, closed
Hoffmann-La Roche
Phase 3
922
Sant Andreu de la Barca, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Granada, Huelva, Madrid, Málaga
2022-07-18
Active, closed
The Left Bundle Cardiac Resynchronization Therapy Trial
NCT05434962Left Bundle-Branch Block, Heart Failure, Impaired Left Ventricular Function
Óscar Cano Pérez
Not applicable
176
Alicante, L'Hospitalet de Llobregat, Granada, Huelva, Madrid, Majadahonda, Murcia, Valencia
2022-06-27
Recruiting
CytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
CytoSorbents, Inc
Observational
3,000
Barcelona, Huelva
2022-06-22
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Gijón, Huelva, Madrid, Seville, Vigo, Villajoyosa
2022-01-19
Active, closed
AbbVie
Observational
873
Badalona, Barcelona, L'Hospitalet de Llobregat, Terrassa, Granada, Huelva, Jaén, Logroño
2021-11-17
Active, closed
AstraZeneca
Phase 3
732
A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2021-10-18
Active, closed
A Non-interventional Cohort Safety Study of Patients With hATTR-PN
NCT04850105Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics
Observational
202
Huelva, Oviedo, Palma de Mallorca, Villarreal, Barcelona, Madrid
2021-09-21
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Almería, Badalona, Barcelona, Boadilla del Monte, Córdoba, El Palmar, Fuencarral-El Pardo, Huelva
2021-08-14
Recruiting
Ipsen
Phase 1/2
240
A Coruña, Barcelona, Huelva, Madrid, Santiago de Compostela, Seville, Vigo
2021-04-29
Recruiting
Natural History of Clostridioides Difficile Infection
NCT04801862Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
Hospital Universitario de Valme
Observational
750
Alicante, Orihuela, Villajoyosa, Puerto Real, Granada, Huelva, Málaga, Valencia
2021-01-01
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
L'Hospitalet de Llobregat, Majadahonda, Barcelona, Bilbao, Huelva, Málaga
2019-11-26
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Huelva, Madrid, Terrassa
2019-09-16
Recruiting
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Observational
1,750
Santiago de Compostela, Córdoba, Granada, Huelva, Málaga, Seville, Huesca, Zaragoza
2019-05-21
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa
2018-12-07
Active, closed
Eli Lilly and Company
Phase 3
1,058
Alicante, Fuenlabrada, Girona, Huelva, Las Palmas de GC, Madrid, Oviedo, Sagunto
2018-07-18
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Córdoba, Ferrol, Girona, Huelva, Madrid, Oviedo, Pontevedra, Seville
2018-04-13
Active, closed
AbbVie
Phase 3
747
Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, A Coruña, Barcelona, Girona, Huelva
2018-03-21
Active, closed
Janssen Biotech, Inc.
Observational
535
A Coruña, Barcelona, Córdoba, Fuenlabrada, Huelva, Madrid, Majadahonda, San Sebastián de los Reyes
2016-12-16
Rows per page Showing 1–73 of 73
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/huelva

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 73 of those studies with a site in Huelva.

How many clinical trials are recruiting in Huelva?

36 of the 73 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 34 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Huelva), 73 studies
PhaseStudiesRecruitingShare
Phase 3351447.9%
Observational241332.9%
Not applicable769.6%
Phase 2526.8%
Phase 1/2111.4%
Phase 2/3101.4%

Most active sponsors

Lead sponsors with the most studies (Huelva)
Lead sponsorStudiesRecruiting
Fundación EPIC64
AstraZeneca54
Novartis Pharmaceuticals51
AbbVie41
Boehringer Ingelheim43
Eli Lilly and Company42
Janssen Research & Development, LLC41
Alnylam Pharmaceuticals32
Merck Sharp & Dohme LLC30
Abivax S.A.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.